Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Akero, AKRO
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.8% on Analyst Upgrade
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00. Morgan Stanley currently has an overweight rating on the stock.
The Akero Therapeutics Inc Rollercoaster: What’s Behind the Latest AKRO Stock Fluctuation?
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and touched a low of $51.
Why Akero Therapeutics, Inc.’s (AKRO) Stock Is Up 97.52%
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to sell.
Akero Therapeutics 5.333M share Secondary priced at $48.00
The deal size was raised to $350M in common stock from $300M in common stock. JPMorgan, Morgan Stanley and Jefferies acted as joint book
Jefferies raises Akero Therapeutics price target to $75
Jefferies analyst Michael Yee increased the price target for Akero Therapeutics stock, listed on (NASDAQ:AKRO), to $75 from the previous $50, while maintaining a Buy rating for the stock. Currently trading at $54,
Akero Therapeutic prices upsized stock offering of $350M
Clinical-stage company developing transformational treatments for patients with serious metabolic disease—Akero Therapeutics (NASDAQ:AKRO) priced of an upsized underwritten public offering of 5.33M shares at $48.
3h
Akero Therapeutics upgraded to Buy from Neutral at BofA
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
STAT
3h
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
2d
on MSN
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Zacks.com on MSN
23h
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
1d
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
1d
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.
1d
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
1d
Some Good MASH/NASH News From Akero Therapeutics
Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...
2d
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
3d
on MSN
Akero soars as drug shows it reverses scarring in liver disease patients
By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback